RxDoctor Payments Data

Rona Holmes, MD

Dermatology · Auburn, ALNPI 1316974090

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,060 of the $10,275 with a category attached, or 68.7%. AbbVie accounts for 80.5% of it on its own, with 23 other manufacturers making up the rest.

$10,275in general payments, 2019–2025

Across 193 payments — averaging $53.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Johnson & Johnson$379
  • Sun Pharmaceutical Industries Inc.$193
  • UCB, Inc.$173
  • Pfizer$171
  • E.r. Squibb & Sons, L.L.C.$141
  • plus $943 from 18 others

What the payments were for

  • Speaking & faculty fees$7,06069%
  • Food & beverage$3,03930%
  • Education$1672%
  • Gifts$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,275 in reported general payments places this provider in the 70th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$192,864
Medicare patients
620
Services billed
4,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa30$622,179
OtezlaApremilast14$68,382
Dupixent PenDupilumab14$53,692
Fluocinonide111$5,190
Metronidazole59$3,834
Ketoconazole214$3,719
Clobetasol Propionate41$2,132
Triamcinolone Acetonide184$1,786
Doxycycline Hyclate95$1,663
CiclopiroxCiclopirox Olamine88$1,656
Fluorouracil23$1,330
ValacyclovirValacyclovir Hcl20$1,297
Clindamycin Phosphate35$1,272
Ciclopirox36$1,190
Betamethasone Dipropionate19$1,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$103$68,38214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 168 dermatology providers in Alabama.

Other dermatology in Auburn

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →